AlphAIAlphAI — Financial news for AI agents
investing.com$BRVE

Goldman Sachs reiterates Braveheart Bio stock buy rating at $48

Goldman Sachs reiterated a buy rating on Braveheart Bio (BRVE) with a $48 price target, suggesting 80% upside from its current price. The biotech firm has a Strong Buy consensus among analysts, with targets ranging from $40 to $48. Recent analyst reports highlight progress in key trials and promising data for BHB-1893, a cardiac myosin inhibitor.

Original reporting
investing.com
Published Sep 14, 2026, 1:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BRVE
Bullish
medium confidence
Mentioned
$BRVE
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BRVEBullishLow
01

Why it matters

Analyst consensus supports current valuation; no new data released.

02

Market read

Analyst rating reaffirmation provides limited trading impetus.

03

What to watch

Potential upcoming trial data could change sentiment.

Relevance 4/10Novelty 2/10Timing: no immediate timing

Background

Goldman Sachs and other analysts maintain bullish ratings on Braveheart Bio.

Company-level read

Ticker impact

$BRVEBullishMedium confidence
Context

Goldman Sachs reiterated a buy rating on Braveheart Bio with a $48 price target.

Expected impact

Modest upside potential if market follows rating.

Evidence & confidence

Rating unchanged; price target unchanged, limited new catalyst.

Market effects

Sector

Reinforces positive outlook for biotech sector analysts.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Rating reiteration may signal lack of new growth catalysts.

Key entities

  • company
    Braveheart Bio

    Biotechnology firm developing cardiac therapies.

Read at source← All news

Related articles

$BRVEMedAI 8/10

Braveheart Bio Reports Positive 52-Week HCM Study Data

Braveheart Bio (BRVE) and Hengrui Pharma presented 52-week Phase 2 study data for HRS/BHB-1893 in obstructive HCM, showing improved exercise capacity and patient outcomes. 79% of 42 patients achieved a Valsalva LVOT gradient below 30 mmHg. The treatment was well-tolerated, with 57% maintaining the starting dose. Analysts rate BRVE stock as Buy with a $40.00 target.

tipranks.com
$BRVEMedAI 8/10

Braveheart Bio Reports 52-Week HRS/BHB-1893 Data in Obstructive HCM

Braveheart Bio reported 52-week Phase 2 extension data for HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy, showing improvements in exercise capacity and patient outcomes. Key metrics: peak oxygen uptake increased by 2.7 mL/kg/min, KCCQ-CSS rose by 17.3 points, and 79% of patients had a Valsalva LVOT gradient below 30 mmHg. The company plans to discuss a Phase 2b study at an investor event.

tradingview.com
$BRVEHighAI 9/10

Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study

Braveheart Bio, Inc. (BRVE) filed an SEC Form 8-K — Regulation FD Disclosure. Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 HRS/BHB-1893 demonstrated meaningful improvements in exercise capaci

SEC EDGAR 8-K
$BRVEMedAI 9/10

Braveheart Bio (BRVE) Reports 52-Week HCM Drug Study Results

Braveheart Bio (BRVE) reported 52-week study results for its HCM drug HRS/BHB-1893, showing improved exercise capacity and symptom scores in 42 patients. 79% had a Valsalva LVOT gradient below 30 mmHg, with no severe adverse events. The company is conducting further studies to establish efficacy and dosing.

tradingview.com